Home / Themes / MedTech Long '24: Lab Research & Trials
MedTech Long '24: Lab Research & Trials (view performance)
Last updated
Theme thesis · 3/5 sections · Tickers 6 with notes · 1 pending
Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).
Bull / Bear DetailsThis basket targets contract research, diagnostics, and lab services companies poised to benefit from a cyclical rebound in biotech funding, a Trump-led push fo
Thesis
This basket targets contract research, diagnostics, and lab services companies poised to benefit from a cyclical rebound in biotech funding, a Trump-led push for domestic reshoring, and a renewed policy and AI-enabled focus on accelerating trials. These firms are critical infrastructure for biopharma innovation, increasingly insulated from China exposure and positioned for long-term demand growth from oncology, rare disease, and gene therapy trials.
Bull case
Biopharma trial volume is rebounding: Clinical activity, biotech funding, and lab demand are accelerating off 2023–24 cyclical lows, as evidenced by improved order books and commentary from CRL and FTRE.
Reshoring tailwinds are material: Trump's trade policy and bipartisan support for onshoring biotech supply chains are driving renewed investment into U.S.-based CROs/CDMOs like NOTV and FTRE.
AI and organoid adoption expands TAM: FDA's push to reduce animal testing via organoids and AI modeling directly boosts demand for proprietary platforms like those at TKNO, CRL, and NOTV, with existing infrastructure benefitting from transition latency
Bear case
Recession stalls clinical activity: A broader economic slowdown could pressure early-stage biotech funding and delay discretionary research contracts.
Regulatory overhaul disappoints: Policy momentum to replace animal testing with AI/organoids may stall due to validation challenges, delaying implementation timelines.
Large-cap clients internalize capacity: Big pharma may reintegrate clinical and manufacturing work in-house, pressuring margins for contract service providers.
Key Metrics
| Metric | Cadence | What It Signals | Update Source |
|---|---|---|---|
| Clinical trial starts by phase and geography | Monthly | Measures demand for CROs, labs, and CDMOs; growth in Phase 1–3 trials = upside. | Google_Sheets |
| Biotech private capital raised (US vs. China) | Monthly/Quarterly | Indicates funding availability for future trial spend; onshoring trend confirmation. | Google_Sheets |
| CRO/CDMO order book growth and bookings | Quarterly | Direct signal on funding trends, client activity, and biopharma outsourcing demand. | Google_Sheets |
Upcoming Catalysts
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type | Catalyst Source |
|---|---|---|---|---|---|---|---|---|---|
| DGX_97da38db | late September, early August | 2026-08-01 | 2026-09-30 | CMS is expected to report on the PAMA data collection process, including an assessment of data quality and the number of labs that submitted data. | The outcome of this report could influence future Medicare reimbursement rates for laboratory testing, potentially impacting Quest Diagnostics' profitability and the broader industry. | Theme | 2026-07-23 | earnings_transcript | DGX (ticker) |
| LH_538b9123 | September 10 | 2026-09-10 | 2026-09-10 | Labcorp Investor Day in New York City. | Management will share more details about their strategy, which could provide insights into future growth drivers, capital allocation, and operational improvements, potentially impacting investor sentiment and stock valuation. | Ticker | 2026-04-30 | earnings_transcript | LH (ticker) |
| LH_e2f765c4 | in the very near future | 2026-07-24 | 2026-10-24 | Completion of the acquisition of select outreach laboratory services across Indiana and Northwest Ohio from Parkview Health. | This acquisition will expand Labcorp's patient and provider networks, increase access to its broad test portfolio, and drive volume growth for the Diagnostics business, positively impacting revenue and competitive position. | Ticker | 2026-04-30 | earnings_transcript | LH (ticker) |
| CRL_76036562 | literally any day now | 2026-09-02 | 2026-09-16 | Resolution of proposed tax legislation changes in Mauritius is expected. | The outcome of this legislation could impact the company's tax rate and earnings per share, with a lower impact potentially providing upside to current guidance. | Ticker | 2026-08-05 | earnings_transcript | CRL (ticker) |
| CRL_938f431a | For the third quarter | 2026-07-01 | 2026-09-30 | Charles River Laboratories expects non-GAAP earnings per share in the range of $2.90 to $3.00 for the third quarter of 2026. | This provides specific financial guidance for the upcoming quarter, indicating strong year-over-year EPS growth, which is a key performance indicator for investors. | Ticker | 2026-08-05 | earnings_transcript | CRL (ticker) |
| CRL_daee1c00 | For the third quarter | 2026-07-01 | 2026-09-30 | Charles River Laboratories expects organic revenue growth of approximately 1% to 3% year-over-year in the third quarter of 2026. | This indicates a continued positive trend in organic revenue growth, driven by improving demand in DSA and a rebound in Biologics Testing, signaling sustained business recovery. | Ticker | 2026-08-05 | earnings_transcript | CRL (ticker) |
| CRL_d18c27a8 | on September 24 | 2026-09-24 | 2026-09-24 | Charles River Laboratories will host an Investor Day to share information about long-term priorities and financial targets. | This event will provide crucial insights into the company's future strategic direction and financial outlook, potentially impacting long-term investor sentiment and valuation. | Ticker | 2026-08-05 | earnings_transcript | CRL (ticker) |
| CRL_bc24e2af | largely benefit the fourth quarter | 2026-10-01 | 2026-12-31 | Lower non-human primate (NHP) sourcing costs from the K.F. Cambodia acquisition are expected to largely benefit the Discovery and Safety Assessment (DSA) operating margin. | This will drive significant margin contribution in the DSA segment, improving profitability and competitive advantage due to more reliable NHP supply. | Ticker | 2026-08-05 | earnings_transcript | CRL (ticker) |
| DGX_ae4871f6 | early next year | 2027-01-01 | 2027-03-31 | Launch of a state-of-the-art lab in Southeast Michigan as part of the joint venture with Corewell Health. | This joint venture is a significant growth driver for Quest's hospital channel, contributing to volume growth and expanding collaborative lab solutions. | Ticker | 2026-04-21 | earnings_transcript | DGX (ticker) |
| DGX_c0c7190c | early next year | 2027-01-01 | 2027-03-31 | Quest Diagnostics anticipates scaling up its Corewell Health Co-Lab relationship to a joint venture and launching a new lab in Michigan. | This represents a significant expansion of a strategic partnership, expected to contribute positively to revenues and strengthen Quest's presence in the hospital channel. | Ticker | 2026-07-23 | earnings_transcript | DGX (ticker) |